Omega-3 Polyunsaturated Fatty Acids and the Resolution of Inflammation: Novel Therapeutic Opportunities for Aortic Valve Stenosis?

Gonzalo Artiach and Magnus Bäck

1 Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2 Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

Inflammation is well-established in cardiovascular disease, including valvular heart disease. Inflammation is a key process in the fibrosis and calcification of the aortic valve leaflets, which ultimately clinically manifest as aortic valve stenosis characterized by valve dysfunction and cardiac obstruction. In the absence of pharmacological treatment, either surgical or transcatheter aortic valve replacement is currently the only available therapeutic strategy for patients with severe aortic valve stenosis. Omega-3 polyunsaturated fatty acids, which exert beneficial effects in several cardiovascular diseases, serve as the substrate for several bioactive lipid mediators that regulate inflammation. Recent findings point to the beneficial effects of omega-3 fatty acids in cardiac valves, being inversely associated with aortic valve calcification and contributing to the resolution of valvular inflammation by means of the pro-resolving mediator resolvin E1 and downstream signaling through its receptor ChemR23.

Keywords: aortic valve stenosis, omega-3 fatty acids, resolution of inflammation, resolvin E1, valvular heart disease

INTRODUCTION

Aortic valve stenosis (AVS) is the most common cause of interventional treatment of the cardiac valves (Nkomo et al., 2006), affecting over 10% of the population above 80 years (Eveborn et al., 2013). AVS is characterized by fibrocalcific aortic valve leaflets with reduced valve opening (Bäck et al., 2013). When AVS becomes severe, significant cardiac outflow obstruction develops, culminating in heart failure and, if untreated, death. Currently, there is no pharmacological treatment for AVS, leaving aortic valve replacement as the only available and effective treatment option.

The aortic valve opens and closes in a coordinated movement, allowing the blood flow from the left ventricle toward the aorta (Bäck et al., 2013). AVS is characterized by an increased inflammation, fibrosis, and calcification of the aortic valve leaflets, which together alter the valvular function. Increased mechanical stress on the aortic valve leads to endothelial injury and subsequent...
activation (Bäck et al., 2013), which, together with inflammatory cell infiltration (New and Aikawa, 2011), lipids and lipoproteins (Smith et al., 2014; Mathieu et al., 2017), extracellular matrix (ECM) remodeling (Aikawa et al., 2007), and oxidative stress (Miller et al., 2010; Mercier et al., 2020), are the key elements for the initiation of the valvular interstitial cell (VIC) calcification characteristic of the disease.

AVS has been associated with inflammation in several studies, manifested systemically by increased levels of C-reactive protein (CRP) (Galante et al., 2001). Calcified regions of stenotic human aortic valves contain infiltration of inflammatory cells (Aikawa et al., 2007), increased levels of inflammatory mediators (Nagy et al., 2011), and decreased levels of anti-inflammatory mediators (Artiach et al., 2020a). The central role of inflammation in AVS has received further support from animal models of aortic valve disease, which have demonstrated an increased lipoprotein infiltration accompanied by endothelial damage, inflammatory cell infiltration, and calcification of the aortic valve (Weiss et al., 2013). Macrophages and other inflammatory cells increase pro-inflammatory cytokines and ECM-degrading enzymes (Aikawa et al., 2007) that may lead to aortic valve thickening and, as a consequence, impaired valvular function. The ECM remodeling as a consequence of proteases and alterations in ECM synthesis will induce the generation of nidus for dystrophic calcification, characteristic in the development of the disease (Rodriguez and Masters, 2009). At later stages, VICs undergo an osteogenic differentiation and contribute to a heterotopic ossification process.

THE RESOLUTION OF INFLAMMATION

The chronic inflammation in AVS, characterized by lipids, lipoproteins, inflammatory cell infiltration, and pro-inflammatory mediators, resembles that observed in atherosclerotic lesions. Importantly, atherosclerotic inflammation is characterized by a failure in the resolution of inflammation (Bäck et al., 2019). Challenging the concept of inflammation as a process that originally was thought to be resolved in a passive manner, the resolution of inflammation has emerged as an active process of limiting inflammatory cell infiltration and favoring phagocytosis for the removal of debris and apoptotic cells from the site of inflammation (Serhan, 2014). Macrophages, predominantly of the M2 subtype, play a key role in these processes (Ariel and Serhan, 2012), but also structural cells actively participate in the resolution of inflammation (Carracedo et al., 2019).

A group of bioactive lipids derived from polyunsaturated fatty acids (PUFAs) and coined specialized pro-resolving mediators (SPMs) are crucial for the resolution of inflammation to take place (Serhan, 2014). In addition to omega-6 PUFA-derived lipoxins, omega-3 PUFAs serve as the substrate for several families of SPMs (Serhan, 2014). Specifically, the D-series resolvins, maresins, and protectins are derived from docosahexaenoic acid (DHA), whereas eicosapentaenoic acid (EPA) gives rise to the E-series resolvins (Serhan and Levy, 2018).

SPMs exert their effects through specific G protein-coupled receptors (Pirault and Back, 2018). For example, resolvin E1 (RvE1) signaling through its receptor ChemR23 limits leukocyte activation (Arita et al., 2005) and enhances phagocytosis in atherosclerosis (Laguna-Fernandez et al., 2018). In addition, RvE1 promotes the anti-inflammatory M2-type macrophage polarization in heart tissue and spleen, shifting the LPS-induced pro-inflammatory M1-type phenotype, observed by increased expression of the M2 macrophage markers arginase 1, CD206, CD163, and CD36 (Zhang et al., 2020).

Stimulating SPMs and their receptors have beneficial effects in several animal models of intimal hyperplasia (Artiach et al., 2018; Liu et al., 2018), atherosclerosis (Petri et al., 2017), and vascular calcification (Carracedo et al., 2018). Recently, studies on SPM pathways (Artiach et al., 2020a) and M2 macrophages (Karadimou et al., 2020) pointed toward a failure in the resolution of inflammation as part of the pathophysiological processes underlying the chronic inflammation in AVS.

SPMs derived from omega-3 PUFA in addition have an important implication from a therapeutic point of view, in terms of omega-3 PUFA supplementation as a potential means of resolving cardiovascular inflammation. Indeed, the levels of CRP in coronary artery disease increase with lower dietary intake of omega-3 PUFA, in particular at an omega-6-to-omega-3 PUFA ratio above 4:1 (Artiach et al., 2020a,b; Sut et al., 2020). This has been further supported by studies in healthy volunteers where a high omega-6-to-omega-3 PUFA ratio is associated with increased levels of inflammatory biomarkers and CRP (Kalogeropoulos et al., 2010). Furthermore, the REDUCE-IT trial recently showed that treatment with EPA ethyl ester formulation in elevated doses conferred a 25% relative risk reduction in major cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, and hospitalization for unstable angina (Bhatt et al., 2019). Whether these beneficial effects of EPA were a result of a modulation of inflammation or/and other cardiovascular risk factors has not been established (Innes and Calder, 2020).

In addition to dietary intake and pharmacological supplementation, the omega-3 and omega-6 PUFA levels are also enzymatically regulated. In particular, the elongation of the very long chain fatty acids protein (ELOVL) together with the fatty acid desaturase (FADS) 1 and 2 catalyze the conversion of alpha-linolenic acid into EPA and DHA (Plunde et al., 2020). Since this variant genotype has been shown to alter both omega-3 and omega-6 PUFA metabolism and to lower AA generation from linoleic acid (Sasakí et al., 2019; Chen et al., 2020), those findings provide a potential link between
PUFA and AVS. This is further reinforced by the finding that higher systemic levels of AA furthermore are associated with aortic valve calcification (Chen et al., 2020). However, the local valve levels rather than systemic levels of PUFA may be decisive for their availabilities as substrates for the biosynthesis of lipid mediators. Therefore, it is of importance that the protective minor allele of the FADS1/2 variant, in addition, confers an increased valvular FADS desaturase activity in the omega-3 PUFA pathway, increasing the amount of DHA in the aortic valve (Plunde et al., 2020). The latter study also showed that DHA levels were lower in calcified compared with non-calcified regions of human stenotic valves, recently extended to an overall decrease in omega-3 PUFA with aortic valve calcification (Artiach et al., 2020a). In addition, subjects with lower valvular omega-3 PUFA index have faster AVS progression prior to aortic valve replacement (Artiach et al., 2020a). Taken together, these studies support the idea that AVS progression and valve calcification are tightly linked to PUFA metabolism in general and to omega-3 PUFA in particular.

LIPOID MEDIATORS AND SPECIALIZED PRO-RESOLVING LIPID MEDIATORS IN AVS

Several pro-inflammatory lipid mediators derived from the omega-6 PUFA metabolome are locally generated in aortic valves. The expression of PUFA-metabolizing enzymes in, and the release of lipid mediators from, human aortic valves and VICS is shown in Table 1. For example, an upregulation of the 5-lipoxygenase pathway in calcified compared with non-calcified aortic valve regions induces a local release of pro-inflammatory leukotriene and correlates with calcification and infiltration of pro-inflammatory cells such as macrophages and T-lymphocytes (Nagy et al., 2011; Kochtebane et al., 2013; Artiach et al., 2020a; Table 1). Furthermore, the cyclooxygenase (COX) 1 and 2 enzymes that are essential for the generation of prostaglandins and thromboxanes from AA are expressed in human aortic valves (Suzuki et al., 2014; Sakaue et al., 2020). Interestingly, COX2 is upregulated in human calcified valves, and its inhibition reduces aortic valve calcification in a klotho-deficient mouse model of cardiovascular calcification via downregulation of osteogenic gene induction (Wirrig et al., 2015). However, the COX2 inhibitor celecoxib has also been associated with increased VIC calcification and AVS (Bowler et al., 2019; Vaidya et al., 2020).

Omega-3 PUFA supplementation decreases the generation of AA-derived lipid mediators generated through the lipoxygenase and COX activities (Ishihara et al., 2019), hence decreasing the inflammatory response. In addition, cytochrome P450-generated epoxygenation products from omega-3 PUFAs may contribute to these anti-inflammatory effects (Ishihara et al., 2019). Preventing subsequent epoxide metabolism through the inhibition of soluble epoxide hydrolase has been shown to sustain the anti-inflammatory actions of the omega-3 PUFA epoxygenation pathway (Zhang et al., 2014). As stated above, lipid mediators, which are enzymatically synthesized from omega-3 PUFAs, may in addition act to actively stop the chronic inflammatory process locally in the aortic valve by promoting the resolution of the inflammation. Indeed, the omega-3 PUFA-derived SPMs RvE1 and RvD3 have been detected using targeted mass spectrometry lipidomic analysis of human valves. RvE1, which is derived from EPA, is furthermore lower in calcified compared with non-calcified regions of aortic valves coming from aortic valve replacement (Artiach et al., 2020a).

These findings indicate that the balance between pro-inflammatory lipid mediators derived from omega-6 PUFA and anti-inflammatory as well as pro-resolving lipid mediators derived from omega-3 PUFA may be decisive whether the PUFA metabolism acts to increase or resolve chronic valvular inflammation. Similar leukotriene-to-resolvin ratios have been proposed as biomarkers in atherosclerosis to detect non-resolving chronic inflammation (Fredman et al., 2016; Thul et al., 2017). The use of SPMs as biomarkers for cardiovascular disease, however, needs further investigation (Calder, 2020).

OMEGA-3 PUFA’S DECREASE AORTIC VALVE DISEASE

Increased systemic omega-3 PUFA as a result of introducing the Fat-1 transgene to hyperlipidemic mice is also reflected in an EPA and DHA enrichment in the aortic valve. The increased systemic and valvular omega-3 PUFA manifested as a hemodynamically reduced cardiac obstruction on echocardiography as well as reduced aortic valve leaflet thickness and calcification on histology (Artiach et al., 2020a). These observations hence provided the proof of concept for beneficial effects of omega-3 PUFA in AVS. The murine mouse model of aortic valve disease used in the latter study is characterized by valvular macrophage infiltration (Tanaka et al., 2005), endothelial activation, calcification, and upregulation of calcification-related proteins (Aikawa et al., 2007). Consistent with a potential stimulation of the resolution of inflammation by means of omega-3 PUFA, mice expressing the Fat-1 transgene exhibit a polarization of the infiltrated valvular macrophages toward an M2 type, observed by increased expression of arginine 1, and a trend towards increased CD206 (Artiach et al., 2020a).

Moreover, deletion of the RvE1 receptor ChemR23 exacerbated aortic valve disease and abolished the beneficial effects of omega-3 PUFA mediated by the transgenic Fat-1 expression, hence reinforcing the idea that the beneficial effects of omega-3 PUFA in aortic valve disease were mediated specifically by the RvE1 and ChemR23 signaling axis, as illustrated in Figure 1 (Artiach et al., 2020a).

MOLECULAR MECHANISMS OF OMEGA-3-DERIVED RVE1 IN AVS

In support of RvE1 signaling affecting the valvular macrophage subtype, the mRNA levels of its receptor ChemR23 are
TABLE 1 | Fatty acid metabolizing enzymes and lipid mediator in human aortic valves.

| Source Method | Result |
|---------------|--------|
| **Fatty acid metabolizing enzymes** |        |
| Cytocoonexygenase-1 Aortic valves IHC | ↑ In AS valves (Suzuki et al., 2014; Sakaue et al., 2020) |
| VIC | ↑ In VIC from calcified valve tissue (Sakaue et al., 2020) |
| Cytocoonexygenase-2 Aortic valves IHC | ↑ In AS valves (Suzuki et al., 2014; Wirrig et al., 2015) |
| 5-Lipoxygenase Aortic valves IHC | ↑ In calcified valve tissue (Nagy et al., 2011; Suzuki et al., 2014) |
| VIC | ↑ After treatment with hypomethylating agent (Nagy and Bäck, 2005) |
| FADS1 and FADS2 Aortic valves Microarray | ↑ In calcified valve tissue (Plunde et al., 2020) |
| **Lipid mediator release** |        |
| PGE2 VIC ELISA | ↑ In VIC from stenotic valve tissue in response to LPS, S1P (Fernandez-Pisonero et al., 2014) |
| LTB4 Aortic valves ELISA | ↑ In AS valves, correlated to degree of calcification (Kochtebane et al., 2013) |
| Aortic valves LC-MS/MS | ↑ In calcified valve tissue (Artiach et al., 2020a) |
| VIC | ↑ After treatment with hypomethylating agent (Nagy and Bäck, 2005) |
| RvD3 Aortic valves LC-MS/MS | ↓ (Trend) in calcified valve tissue (Artiach et al., 2020a) |
| RvE1 Aortic valves LC-MS/MS | ↓ In calcified valve tissue (Artiach et al., 2020a) |

AS, aortic stenosis; FADS, fatty acid desaturase; ICC, immunocytochemistry; IHC, immunohistochemistry; LC-MS/MS, liquid chromatography tandem mass spectrometry; LTB4, leukotriene B4; LPS, lipopolysaccharide; PGE2, prostaglandin E2; qPCR, quantitative polymerase chain reaction; RvD3, resolvin D3; RvE1, resolvin E1; S1P, shingosine-1-phosphate; VIC, valvular interstitial cell.

significantly correlated with the expression of markers of M2-type macrophages in human stenotic valves (Artiach et al., 2020a). Similar associations have been reported also for Toll-like receptor (TLR) 7 in stenotic aortic valves and stimulation of macrophages with a TLR7 agonist induced release of the anti-inflammatory cytokine IL-10 (Karadimou et al., 2020), hence reinforcing the role of M2 macrophages in the resolution of valvular inflammation. Moreover, exogenous administration of RvE1 to cultured VIC reduced in vitro calcification, suggesting that omega-3 PUFA-derived SPMs in addition to altering the valvular immune response also directly act on the structural cells of the valve to counteract calcification. Similar findings are observed after RvE1 administration to vascular smooth muscle cells, where the reduced calcification by RvE1 is associated...
to lower expression levels of bone morphogenetic protein 2 (Carracedo et al., 2018).

The in vivo situation may however be more complex. ChemR23 has been identified as a transducer of opposing effects in different cell types in terms of, for example, blocking inflammatory activation of macrophages, leading to a reduced smooth muscle cell proliferation in a mouse model of intimal hyperplasia, but stimulating vascular smooth muscle cell proliferation in vitro when inflammatory cells are not present (Artiach et al., 2018). Furthermore, in contrast to the exacerbated aortic valve calcification after ChemR23 knockout in hyperlipidemic mice, a non-inflammation-dependent mouse model of vascular calcification induced by vitamin D3 displayed reduced vascular calcification after genetic deletion of ChemR23 (Carracedo et al., 2018). These observations hence indicate a close interplay between immune cells and structural cells in the cardiovascular system where the phenotype favored by SPM receptors may depend on the degree of inflammation (Carracedo et al., 2019).

**DISCUSSION**

Omega-3 PUFA exert a plethora of beneficial effects. One of the potential underlying mechanisms is by serving as substrate for SPM biosynthesis and mediating the resolution of inflammation (Serhan and Levy, 2018). Stimulating the resolution of inflammation to target chronic inflammation is an emerging concept as an alternative to anti-inflammatory treatment with the advantage to avoid immunosuppression. The applicability of the concept has been explored in atherosclerosis treatment with the advantage to avoid immunosuppression. The resolution of inflammation to target chronic inflammation is an emerging concept as an alternative to anti-inflammatory treatment (Bhatt et al., 2019). Here, we provide arguments from recent studies that these beneficial effects of omega-3 PUFA extend to also AVS.

Increased systemic and valvular inflammation in patients with AVS may be a key pathophysiological process leading to increased calcification of the aortic valve and ultimately clinically manifested AVS. Omega-3 PUFA accumulates in both human and murine aortic valves (Artiach et al., 2020a; Plunde et al., 2020) and contributes to the formation of the SPM RvE1, which signals through its receptor ChemR23 to transduce the resolution of valvular inflammation. In this process RvE1-induced M2 macrophage polarization and direct anti-calcifying effects result in decreased hemodynamic and morphological signs of aortic valve disease (Artiach et al., 2020a).

Taken together, the preclinical and clinical findings on FADS/FADS 2 genotype, omega-3 PUFA, the EPA-derived SPM RvE1, and its receptor ChemR23 on aortic valve function and structure described in this review may open up novel clinical opportunities toward a medical therapy to prevent AVS and valvular calcification. In particular, the potential beneficial effects of omega-3 PUFA supplementation in AVS warrant further investigation in clinical trials.

**AUTHOR CONTRIBUTIONS**

GA and MB wrote the article. Both authors contributed to the article and approved the submitted version.

**FUNDING**

The authors were supported by the Swedish Research Council (Grant No. 2019-01486), the Swedish Heart and Lung Foundation (Grant Nos. 20180571 and 20180572), King Gustaf V and Queen Victoria Freemason Foundation, and the Stockholm County Council (Grant No. 20170365).

**REFERENCES**

Aikawa, E., Nahrenendorf, M., Sosnovik, D., Lok, V. M., Jaffer, F. A., Aikawa, M., et al. (2007). Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. *Circulation* 115, 377–386. doi: 10.1161/CIRCULATIONAHA.106.654913

Ariel, A., and Serhan, C. N. (2012). New lives given by cell death: macrophage differentiation following their encounter with apoptotic leukocytes during the resolution of inflammation. *Front. Immunol.* 3:4. doi: 10.3389/fimmu.2012.00004

Arita, M., Bianchini, F., Alberti, J., Sher, A., Chiang, N., Hong, S., et al. (2005). Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J. Exp. Med.* 201, 713–722. doi: 10.1084/jem.20042031

Artiach, G., Carracedo, M., Clària, J., Laguna-Fernandez, A., and Bäck, M. (2018). Opposing effects on vascular smooth muscle cell proliferation and macrophage-induced inflammation reveal a protective role for the proresolving lipid mediator receptor Chemr23 in intimal hyperplasia. *Front. Pharmacol.* 9:1327. doi: 10.3389/fphar.2018.01327

Artiach, G., Carracedo, M., Plunde, O., Wheelock, C. E., Thul, S., Sjovall, P., et al. (2020a). Omega-3 polyunsaturated fatty acids decrease aortic valve disease through the resolvin E1 and ChemR23 axis. *Circulation* 142, 776–789. doi: 10.1161/CIRCULATIONAHA.119.041868

Artiach, G., Sarajlic, P., and Bäck, M. (2020b). Inflammation and its resolution in coronary artery disease: a tightrope walk between omega-6 and omega-3 polyunsaturated fatty acids. *Kardiol. Pol.* 78, 93–95. doi: 10.33963/KP.15202

Bäck, M., Gasser, T. C., Michel, J. B., and Caligiuri, G. (2013). Biomechanical factors in the biology of aortic wall and aortic valve diseases. *Cardiovasc. Res.* 99, 232–241. doi: 10.1093/cvr/cvt040

Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., and Kovanen, P. T. (2019). Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. *Nat. Rev. Cardiol.* 16, 389–406. doi: 10.1038/s41569-019-0169-2

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N. Engl. J. Med.* 380, 11–22. doi: 10.1056/NEJMoai1812792

Bowler, M. A., Raddatz, M. A., Johnson, C. L., Lindman, B. R., and Merryman, W. D. (2019). Celecoxib is associated with dystrophic calcification and aortic valve stenosis. *JACC Basic Transl. Sci.* 4, 135–143. doi: 10.1016/j.jacbts.2018.12.003

Calder, P. C. (2020). Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake. *Biochimie* 178, 105–123. doi: 10.1016/j.biochi.2020.08.015

Carracedo, M., Artiach, G., Arnardottir, H., and Bäck, M. (2019). The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal
Yuan, S., Bäck, M., Bruzelius, M., Mason, A. M., Burgess, S., and Larsson, S. (2019). Plasma phospholipid fatty acids, FADS1 and risk of 15 cardiovascular diseases: a mendelian randomisation study. *Nutrients* 11:3001. doi: 10.3390/nu11123001

Zhang, G., Kodani, S., and Hammock, B. D. (2014). Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. *Prog. Lipid. Res.* 53, 108–123. doi: 10.1016/j.plipres.2013.11.003

Zhang, J., Wang, M., Ye, J., Liu, J., Xu, Y., Wang, Z., et al. (2020). The anti-inflammatory mediator resolvin e1 protects mice against lipopolysaccharide-induced heart injury. *Front. Pharmacol.* 11:203. doi: 10.3389/fphar.2020.00203

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Artiach and Bäck. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.